文献
J-GLOBAL ID:202202230548777600
整理番号:22A0798485
強力の原発性結果: 未治療の尿路上皮癌患者における定用量デュルバルマブ単独療法のオープンラベル,多施設,第3b相試験【JST・京大機械翻訳】
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
著者 (21件):
Sonpavde Guru P.
(Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA)
,
Sternberg Cora N.
(Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Sandra and Edward Meyer Cancer Center, Hematology/Oncology, 413 E 69th Street, Belfer Research Building, New York, NY 10021, USA)
,
Sternberg Cora N.
(Presbyterian Hospital, 1305 York Avenue, New York, NY 10021, USA)
,
Loriot Yohann
(Department of Cancer Medicine, Gustave Roussy, Universite Paris-Saclay, Villejuif, France)
,
Marabelle Aurelien
(Department of Cancer Medicine, Gustave Roussy, Universite Paris-Saclay, Villejuif, France)
,
Lee Jae Lyun
(Department of Oncology and Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul 05505, South Korea)
,
Flechon Aude
(Department of Medical Oncology, Centre Leon-Berard, 28 Rue Laennec, 69008 Lyon, France)
,
Roubaud Guilhem
(Medical Oncology, Institut Bergonie, 229 Cours de l’Argonne, 33000 Bordeaux, France)
,
Pouessel Damien
(Medical Oncology Department, Institut Claudius Regaud, IUCT Oncopole, 1 avenue Irene Joliot-Curie, 31059 Toulouse Cedex 9, Toulouse, France)
,
Zagonel Vittorina
(Oncology Department, Oncology Unit 1, Veneto Institute of Oncology, IOV, IRCCS, Padua, Italy)
,
Calabro Fabio
(Medical Oncology, San Camillo Forlanini Hospital, 75 Circonvallazione Gianicolense, 00152 Rome RM, Italy)
,
Banna Giuseppe L.
(Department of Oncology, Ospedale Cannizzaro, 95126 Catania, Province of Catania, Italy)
,
Shin Sang Joon
(Department of Internal Medicine, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea)
,
Vera-Badillo Francisco E.
(Department of Oncology, Queen’s University, 25 King St W, K7L 5P9, Kingston, Ontario, Canada)
,
Powles Thomas
(Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Mile End Road, London E1 4NS, UK)
,
Hellmis Eva
(Institut Urologicum Duisburg, Kometenplatz 29-33, 47179, Duisburg, Germany)
,
Miranda Paulo A.P.
(Oncology Business Unit (OBU), Global Medical Affairs, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, USA)
,
Lima Ana Rita
(Oncology Business Unit (OBU), Global Medical Affairs, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, USA)
,
Emeribe Ugochi
(Statistical Science Immuno-Oncology, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, USA)
,
Oh Sun Min
(Oncology Business Unit (OBU), Global Medical Affairs, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878, USA)
,
Hotte Sebastien J.
(Department of Oncology, Juravinski Cancer Centre (JCC), Hamilton Health Sciences 699 Concession Street, Hamilton, ON, Canada)
資料名:
European Journal of Cancer
(European Journal of Cancer)
巻:
163
ページ:
55-65
発行年:
2022年
JST資料番号:
A0802C
ISSN:
0959-8049
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)